6/27/2025

Janusmed sex and gender

Janusmed sex and gender – Trametinib

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
C! C!
C! C!

Trametinib

Trametinib

Class : C!

Show all info

Print

Contact us

  1. Mekinist (trametinib). Summary of Product Characteristics. European Medicines Agency [updated 2024-05-30, cited 2024-06-14]

  2. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626-38.

  3. Vellano CP, White MG, Andrews MC, Chelvanambi M, Witt RG, Daniele JR et al. Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature. 2022;606(7915):797-803.

  4. Ouellet D, Kassir N, Chiu J, Mouksassi MS, Leonowens C, Cox D et al. Population pharmacokinetics and exposure-response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma. Cancer Chemother Pharmacol. 2016;77(4):807-17.

  5. Food and Drug Administration (FDA). Pharmacology Review - Mekinist (trametinib). Drugs@FDA [www]. [updated 2013-07-08, cited 2024-06-14].

  6. Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E et al. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. N Engl J Med. 2019;381(7):626-636.

  7. Government of Canada. Mekinist (trametinib) - Product Monograph. Drug Product Database (DPD) [www]. [updated 2019-04-05, cited 2024-06-14].

  8. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2023 [cited 2024-03-06.]

  1. Mekinist (trametinib). Summary of Product Characteristics. European Medicines Agency [updated 2024-05-30, cited 2024-06-14]
  2. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626-38.
  3. Vellano CP, White MG, Andrews MC, Chelvanambi M, Witt RG, Daniele JR et al. Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature. 2022;606(7915):797-803.
  4. Ouellet D, Kassir N, Chiu J, Mouksassi MS, Leonowens C, Cox D et al. Population pharmacokinetics and exposure-response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma. Cancer Chemother Pharmacol. 2016;77(4):807-17.
  5. Food and Drug Administration (FDA). Pharmacology Review - Mekinist (trametinib). Drugs@FDA [www]. [updated 2013-07-08, cited 2024-06-14].
  6. Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E et al. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. N Engl J Med. 2019;381(7):626-636.
  7. Government of Canada. Mekinist (trametinib) - Product Monograph. Drug Product Database (DPD) [www]. [updated 2019-04-05, cited 2024-06-14].
  8. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2023 [cited 2024-03-06.]